LL-37 Research Reporting Standards

LL-37 research reporting standards are the documentation conventions that make a peptide lot traceable, comparable, and defensible on paper: identity confirmed by mass spectrometry, purity reported by HPLC with the analytical method stated alongside it, net peptide content separated from gross fill weight, counterion and residual solvent disclosed, endotoxin and microbial results tied to a named batch, and a certificate of analysis that belongs to the specific lot in the box rather than to a representative sample from some earlier production run. For a wholesale buyer, that list doubles as a purchasing checklist. If a supplier cannot produce those items on request, you are not buying a characterized research compound — you are buying a label.

All compounds discussed here are research use only. Nothing below describes administration, dosing, or use in people or animals.

What a complete data package for an antimicrobial peptide contains

LL-37 is the mature, active fragment of human cathelicidin, a 37-residue cationic peptide studied extensively in host-defense, membrane-interaction, and immunomodulatory literature. Because it is long, highly charged, and prone to aggregation and surface adsorption, it is unusually sensitive to how it was made, purified, dried, and stored. That sensitivity is exactly why reporting conventions exist.

A complete package generally includes: a mass spectrometry trace or reported observed mass against theoretical mass, so identity is confirmed rather than assumed; an HPLC chromatogram with the gradient, column, and detection wavelength named; net peptide content, usually by amino acid analysis or nitrogen determination; counterion identity and content, since trifluoroacetate from reverse-phase purification travels with the peptide; residual water content, typically by Karl Fischer or loss on drying; endotoxin results where the material is intended for cell-based work; and appearance, solubility notes, and storage conditions.

Each of those lines answers a different question. Purity tells you what fraction of the chromatographic peak area is your target sequence. Net peptide content tells you how much of the vial's mass is actually peptide rather than salt and water. Identity tells you it is the right molecule. Missing any one of them makes the other two harder to interpret, and makes two lots from two vendors genuinely non-comparable no matter how similar their headline numbers look.

A purity figure means nothing without the method beside it

The single most common reporting failure in this category is a purity percentage floating on a certificate with no method attached. Area-percent purity from reverse-phase HPLC depends on the gradient, the column chemistry, the detection wavelength, and the run length. A shallow gradient over a long run resolves closely eluting impurities. A fast, steep gradient can bury them under the main peak and return a flattering number from the same material.

So the standard is not "report purity." The standard is "report purity with the conditions that produced it, and supply the chromatogram." A buyer who receives the trace can see peak shape, baseline, retention time, and whether there are shoulders that a percentage alone would hide. A buyer who receives only a number is trusting an unaudited claim.

The same logic applies to mass spectrometry. An observed mass without the instrument type and the theoretical mass it was compared against is a fragment of a result. For a peptide of this length, deamidation, oxidation of methionine, and truncation products are the realistic impurity classes, and they are visible in a properly reported spectrum.

Reading a certificate of analysis line by line

Use the table below as a working checklist when you evaluate any supplier's documentation, for this compound or any other in your purchase order.

If a supplier treats any row in that table as proprietary, that is information in itself.

Why antimicrobial peptide results are easy to misread

Beyond the certificate, the published literature on cathelicidin peptides carries its own reporting conventions, and they matter to anyone deciding what to stock and how to describe it accurately in a catalog.

Research suggests that LL-37 activity in laboratory assays is strongly condition-dependent. Salt concentration, serum or plasma protein content, media composition, and even the plastic the assay runs in can shift outcomes, because cationic peptides adsorb to surfaces and bind serum components. This is why methods papers in the antimicrobial peptide field emphasize reporting buffer composition, cation content, inoculum size, and plate material — variables a general reader might skim past. Two studies reporting different results are often not in conflict; they ran different assays.

Studies also indicate that these peptides aggregate and adopt different secondary structures depending on concentration and environment, which is another reason stock preparation details belong in a methods section rather than being left implicit. For a wholesale buyer, the practical takeaway is narrow but important: be conservative in how you characterize any research compound in your own product copy. Describe what the literature investigates, hedge honestly, and never translate a laboratory finding into an implied outcome. That restraint protects your business far more than enthusiastic copy ever will.

Questions worth putting to any wholesale supplier

Supplier evaluation is mostly a documentation audit. A few questions separate programs quickly.

Are certificates of analysis batch-specific, and can you see them before you commit to an order? Some programs publish COAs openly. Others provide a generic specimen document, or charge for the real one, or produce it only after payment clears. The difference is not cosmetic — a representative COA tells you what a good lot looked like once, not what this lot is.

Who performed the testing, and is third-party analysis available? In-house data is not automatically suspect, but independent confirmation is the stronger position, and a supplier confident in its material tends to welcome the question.

Is every batch tested, or is testing sampled across a campaign? Batch-level testing costs more and is the more rigorous standard.

How is pricing structured? Wholesale terms that only appear after a sales call, with tier thresholds you cannot see in advance, make it impossible to model your own purchasing. Margins and minimums vary widely by category and volume across this industry, so what matters is not a benchmark number but whether the structure is disclosed to you in writing before you buy.

Finally, where does fulfillment originate, and what are the stated handling and shipping windows? Long or vague transit paths introduce temperature exposure and customs variables that no certificate can retroactively fix.

Where compliance questions belong

Research peptides sit in a regulatory space that rewards caution and punishes assumption. The compounds discussed here are not approved drugs and are not for human or animal consumption. Beyond that, the questions a business buyer needs answered are genuinely questions, not settled facts, and they belong with qualified counsel rather than a blog post.

Ask your attorney and, where relevant, your state licensing board: how does our state characterize the resale of research-use-only materials, and does our entity type change that answer? What labeling language is required or prohibited on anything we relabel or resell? Does our marketing copy create claims that shift a product into a regulated category? What recordkeeping should we maintain on lot traceability and supplier documentation? How do advertising standards apply to how we describe research compounds online?

This section is informational and is not legal advice. The framework varies by jurisdiction and by business model, and the only reliable answer is the one your own counsel gives you in writing after reviewing your specific operation.

What Real Peptides does differently

Real Peptides built its Wholesale Partner Program around the documentation gap described above rather than around price alone.

Compounds are produced to 99%+ HPLC purity. Every batch goes through seven-panel testing rather than sampled campaign testing, so the analysis attaches to the lot rather than to a production window. Certificates of analysis are publicly verifiable — a prospective partner can review lab results directly instead of requesting a specimen document, waiting for a sales call, or paying separately for the data that should have accompanied the product. That transparency is the point: it lets a buyer audit the supplier before placing an order rather than after.

Fulfillment runs from within the US, with orders shipping in five to seven days. Wholesale access is a three-step application rather than an open-ended negotiation, and pricing tiers are disclosed to approved partners rather than revealed piecemeal.

None of that is a promise about your business results, and it should not be read as one. It is a description of what arrives with the product and what you can verify yourself before committing capital to inventory.

If you operate a med spa, clinic, telehealth practice, or reseller brand and you are building a catalog on suppliers whose documentation you can actually audit, the Wholesale Partner Program application is the next step — three steps to review, approval, and tier pricing, with the lab data available to examine beforehand.

For context on the breadth of the catalog, partners commonly evaluate documentation across the popular peptides range alongside category-specific lines such as gastrointestinal and epithelial research compounds, where immune-signaling research interest overlaps — KPV being a frequently reviewed example — and the growth factor and tissue signaling research collection, each carrying the same batch-level certificate standard.